IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms.
IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms.
复制标题
DOI：
10.1186/s13550-017-0339-3
复制
发表时间：
2017-11-03
期刊：
影响因子：
3.2
通讯作者：
Mattsson S
中科院分区：
文献类型：
--
作者：
Andersson M;Johansson L;Eckerman K;Mattsson S
迄今为止，接受核医学诊断检查的患者器官和组织的辐射吸收剂量的估计值是通过基于人体模型和放射性药物的生物动力学行为的计算得出的。内部剂量测定计算机程序 IDAC-Dose2.1 是根据国际放射防护委员会 (ICRP) 特定吸收分数和 ICRP 第 133 号出版物中为参考成人给出的内部剂量评估计算框架开发的。该程序使用 ICRP 第 107 号出版物的放射性核素衰变数据库，并考虑照射 47 个靶组织的 83 个不同源区域，将有效剂量定义为 ICRP 出版物 60 和 103 中介绍了该计算机程序。该计算机程序针对另一个 ICRP 剂量测定程序“剂量和风险计算”(DCAL) 进行了验证，该程序采用相同的计算框架来评估放射性核素的职业和环境摄入量。 IDAC-Dose2.1有一个子模块，用于计算不同体积和成分的球形结构的吸收剂量；该子模块用于放射性药物治疗中的吸收剂量估计。对于九种特定的α发射体，其衰变产物的吸收剂量贡献也包含在承诺吸收剂量计算中。 IDAC-Dose2.1 测定的 131I-碘化物的吸收剂量和有效剂量根据剂量测定程序 DCAL 进行了验证，显示出相同的结果。 IDAC-Dose2.1 用于计算静脉注射 18F-FDG 和口服 99mTc-高锝酸盐和 131I-碘化物（三种常用放射性药物）的吸收剂量。使用 ICRP 出版物 103 中的组织权重因子，估计 18F-FDG 的每次给药活动的有效剂量为 0.016 mSv/MBq，99mTc-pertechnetate 的有效剂量为 0.014 mSv/MBq，131I-碘化物的有效剂量为 16 mSv/MBq。开发了内部剂量测定程序 IDAC-Dose2.1，并将其应用于三种放射性药物，以针对 DCAL 进行验证，并使用 ICRP 计算体素模型的特定吸收分数值生成改进的吸收剂量估计，用于诊断核医学。包含用于计算直径 1 毫米至 9 厘米的球形结构和不同组织成分的吸收剂量的子模块，以扩大该程序的临床用途。 IDAC-Dose2.1 程序是用于研究的免费软件，可从 http://www.idac-dose.org 下载。
To date, the estimated radiation-absorbed dose to organs and tissues in patients undergoing diagnostic examinations in nuclear medicine is derived via calculations based on models of the human body and the biokinetic behaviour of the radiopharmaceutical. An internal dosimetry computer program, IDAC-Dose2.1, was developed based on the International Commission on Radiological Protection (ICRP)-specific absorbed fractions and computational framework of internal dose assessment given for reference adults in ICRP Publication 133. The program uses the radionuclide decay database of ICRP Publication 107 and considers 83 different source regions irradiating 47 target tissues, defining the effective dose as presented in ICRP Publications 60 and 103. The computer program was validated against another ICRP dosimetry program, Dose and Risk Calculation (DCAL), that employs the same computational framework in evaluation of occupational and environmental intakes of radionuclides. IDAC-Dose2.1 has a sub-module for absorbed dose calculations in spherical structures of different volumes and composition; this sub-module is intended for absorbed dose estimates in radiopharmaceutical therapy. For nine specific alpha emitters, the absorbed dose contribution from their decay products is also included in the committed absorbed dose calculations. The absorbed doses and effective dose of 131I-iodide determined by IDAC-Dose2.1 were validated against the dosimetry program DCAL, showing identical results. IDAC-Dose2.1 was used to calculate absorbed doses for intravenously administered 18F-FDG and orally administered 99mTc-pertechnetate and 131I-iodide, three frequently used radiopharmaceuticals. Using the tissue weighting factors from ICRP Publication 103, the effective dose per administered activity was estimated to be 0.016 mSv/MBq for 18F-FDG, 0.014 mSv/MBq for 99mTc-pertechnetate, and 16 mSv/MBq for 131I-iodide. The internal dosimetry program IDAC-Dose2.1 was developed and applied to three radiopharmaceuticals for validation against DCAL and to generate improved absorbed dose estimations for diagnostic nuclear medicine using specific absorbed fraction values of the ICRP computational voxel phantoms. The sub-module for absorbed dose calculations in spherical structures 1 mm to 9 cm in diameter and different tissue composition was included to broaden the clinical usefulness of the program. The IDAC-Dose2.1 program is free software for research and available for download at http://www.idac-dose.org.
登录
查看更多内容
影响因子：
4
作者：
Andersson M
通讯作者：
Andersson M
影响因子：
--
作者：
Bolch, W. E.;Jokisch, D.;Petoussi-Henss, N.
通讯作者：
Petoussi-Henss, N.
影响因子：
9.3
作者：
Bolch, Wesley E.;Eckerman, Keith F.;Thomas, Stephen R.
通讯作者：
Thomas, Stephen R.
影响因子：
1
作者：
Andersson, M.;Johansson, L.;Leide-Svegborn, S.
通讯作者：
Leide-Svegborn, S.
影响因子：
1.5
作者：
Leggett, R.;Giussani, A.
通讯作者：
Giussani, A.